Clinical Trials Browser

Approved for marketing × INDUSTRY × Lung Neoplasms × Clear all

NCT06064500 2025-03-10

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Approved for marketing

Bites and Stings, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04829422 2022-03-03

Early Access Program of Lazertinib in Republic of Korea

Approved for marketing

Lung Neoplasms

NCT04504513 2021-03-19

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Approved for marketing

Lung Neoplasms, Small Cell Lung Carcinoma